Ottobock stock backs Blue Arbor prosthetic-control program

Blue Arbor Technologies closed a 10.5 million US-dollar Series A financing round on October 29, led by strategic partner Ottobock, according to BioSpace. The funding strengthens Ottobock's position in the development of advanced prosthetic-control technology, while the financial impact on current revenue is not specified.

Funding targets clinical development

Blue Arbor plans to use the proceeds to complete feasibility testing for its RESTORE Neuromuscular Interface System and pursue a U.S. Food and Drug Administration Investigational Device Exemption. The financing also supports U.S. clinical studies for the external sensing unit and the start of development for a fully implantable internal sensing unit.

RESTORE is designed to enable independent and simultaneous control of a prosthesis' fingers, wrist and elbow. Blue Arbor is developing both an external interface and an implantable version that connects the patient's peripheral nervous system with a robotic prosthetic limb.

Milestones remain investigational

Blue Arbor said two human implantations had been completed, including a second-in-human procedure using the external sensing unit at the Medical University of Vienna. The system has also been selected for a University of Michigan clinical study funded by a UG3 grant from the National Institutes of Health. That study will compare surface electrodes with implanted electrodes for prosthetic control.

RESTORE has received FDA Breakthrough Device Designation and entered the FDA's Total Product Life Cycle Advisory Program Pilot. Those milestones support the development path but do not constitute commercial approval. Blue Arbor states that the system remains investigational and is not approved or cleared for commercial distribution.

Stock context for investors

Ottobock stock traded at 47.53 euros on Lang & Schwarz at 11:36 CET on Tuesday, November 3, 2026. Investors should view the Blue Arbor financing as a strategic technology investment whose potential depends on clinical evidence, regulatory progress and eventual adoption.

Ottobock's real-time quote of Ottobock stock provides the latest trading indication.

European healthcare and medical-technology shares trade against a broader market backdrop reflected in the DAX.

Further clinical and regulatory progress on RESTORE will be the next material milestones for Ottobock's strategic exposure to neuromuscular interfaces. More news and analyses on Ottobock stock.